TY  - CHAP
M1  - Book, Section
TI  - Noninfectious Pulmonary Complications of Hematopoietic Stem Cell and Solid Organ Transplantation
A1  - Yadav, Hemang
A1  - Peters, Steve G.
A1  - Kotloff, Robert M.
A2  - Grippi, Michael A.
A2  - Antin-Ozerkis, Danielle E.
A2  - Dela Cruz, Charles S.
A2  - Kotloff, Robert M.
A2  - Kotton, Camille Nelson
A2  - Pack, Allan I.
PY  - 2023
T2  - Fishman’s Pulmonary Diseases and Disorders, 6e
AB  - Hematopoietic  stem-cell  transplantation  (HSCT)  is  a  potentially  curative  treatment  option  for  hematologic  and  lymphoid  cancers,  selected  solid  tumors,  and  nonneoplastic  diseases,  including  autoimmune  disorders,  amyloidosis,  and  aplastic  anemia.1  Since  the  first  HSCT  was  performed  in  1956,  there  has  been  a  steady  increase  in  the  number  performed  worldwide,  with  more  than  35,000  autologous  and  30,000  allogeneic  HSCTs  now  performed  annually.2  In  the  United  States  in  2018,  a  total  of  9028  allogeneic  and  14,006  autologous  HSCTs  were  performed.3  As  peritransplant  management  strategies  have  improved,  HSCTs  are  being  performed  increasingly  often  for  a  wider  range  of  conditions,  and  in  patients  who  are  older  and  with  more  comorbidities.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/24
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1195010975
ER  -